Structural Considerations for Building Synthetic Glycoconjugates as Inhibitors for Pseudomonas aeruginosa Lectins. Wojtczak, K. & Byrne, J. P. ChemMedChem, 17(12):e202200081, 2022. _eprint: https://onlinelibrary.wiley.com/doi/pdf/10.1002/cmdc.202200081Paper doi abstract bibtex Pseudomonas aeruginosa is a pathogenic bacterium, responsible for a large portion of nosocomial infections globally and designated as critical priority by the World Health Organisation. Its characteristic carbohydrate-binding proteins LecA and LecB, which play a role in biofilm-formation and lung-infection, can be targeted by glycoconjugates. Here we review the wide range of inhibitors for these proteins (136 references), highlighting structural features and which impact binding affinity and/or therapeutic effects, including carbohydrate selection; linker length and rigidity; and scaffold topology, particularly for multivalent candidates. We also discuss emerging therapeutic strategies, which build on targeting of LecA and LecB, such as anti-biofilm activity, anti-adhesion and drug-delivery, with promising prospects for medicinal chemistry.
@article{wojtczak_structural_2022,
title = {Structural {Considerations} for {Building} {Synthetic} {Glycoconjugates} as {Inhibitors} for {Pseudomonas} aeruginosa {Lectins}},
volume = {17},
copyright = {All rights reserved},
issn = {1860-7187},
url = {https://onlinelibrary.wiley.com/doi/abs/10.1002/cmdc.202200081},
doi = {10.1002/cmdc.202200081},
abstract = {Pseudomonas aeruginosa is a pathogenic bacterium, responsible for a large portion of nosocomial infections globally and designated as critical priority by the World Health Organisation. Its characteristic carbohydrate-binding proteins LecA and LecB, which play a role in biofilm-formation and lung-infection, can be targeted by glycoconjugates. Here we review the wide range of inhibitors for these proteins (136 references), highlighting structural features and which impact binding affinity and/or therapeutic effects, including carbohydrate selection; linker length and rigidity; and scaffold topology, particularly for multivalent candidates. We also discuss emerging therapeutic strategies, which build on targeting of LecA and LecB, such as anti-biofilm activity, anti-adhesion and drug-delivery, with promising prospects for medicinal chemistry.},
language = {en},
number = {12},
urldate = {2022-09-07},
journal = {ChemMedChem},
author = {Wojtczak, Karolina and Byrne, Joseph P.},
year = {2022},
note = {\_eprint: https://onlinelibrary.wiley.com/doi/pdf/10.1002/cmdc.202200081},
pages = {e202200081},
}
Downloads: 0
{"_id":"J7PsERNPJ22QC9ybL","bibbaseid":"wojtczak-byrne-structuralconsiderationsforbuildingsyntheticglycoconjugatesasinhibitorsforpseudomonasaeruginosalectins-2022","author_short":["Wojtczak, K.","Byrne, J. P."],"bibdata":{"bibtype":"article","type":"article","title":"Structural Considerations for Building Synthetic Glycoconjugates as Inhibitors for Pseudomonas aeruginosa Lectins","volume":"17","copyright":"All rights reserved","issn":"1860-7187","url":"https://onlinelibrary.wiley.com/doi/abs/10.1002/cmdc.202200081","doi":"10.1002/cmdc.202200081","abstract":"Pseudomonas aeruginosa is a pathogenic bacterium, responsible for a large portion of nosocomial infections globally and designated as critical priority by the World Health Organisation. Its characteristic carbohydrate-binding proteins LecA and LecB, which play a role in biofilm-formation and lung-infection, can be targeted by glycoconjugates. Here we review the wide range of inhibitors for these proteins (136 references), highlighting structural features and which impact binding affinity and/or therapeutic effects, including carbohydrate selection; linker length and rigidity; and scaffold topology, particularly for multivalent candidates. We also discuss emerging therapeutic strategies, which build on targeting of LecA and LecB, such as anti-biofilm activity, anti-adhesion and drug-delivery, with promising prospects for medicinal chemistry.","language":"en","number":"12","urldate":"2022-09-07","journal":"ChemMedChem","author":[{"propositions":[],"lastnames":["Wojtczak"],"firstnames":["Karolina"],"suffixes":[]},{"propositions":[],"lastnames":["Byrne"],"firstnames":["Joseph","P."],"suffixes":[]}],"year":"2022","note":"_eprint: https://onlinelibrary.wiley.com/doi/pdf/10.1002/cmdc.202200081","pages":"e202200081","bibtex":"@article{wojtczak_structural_2022,\n\ttitle = {Structural {Considerations} for {Building} {Synthetic} {Glycoconjugates} as {Inhibitors} for {Pseudomonas} aeruginosa {Lectins}},\n\tvolume = {17},\n\tcopyright = {All rights reserved},\n\tissn = {1860-7187},\n\turl = {https://onlinelibrary.wiley.com/doi/abs/10.1002/cmdc.202200081},\n\tdoi = {10.1002/cmdc.202200081},\n\tabstract = {Pseudomonas aeruginosa is a pathogenic bacterium, responsible for a large portion of nosocomial infections globally and designated as critical priority by the World Health Organisation. Its characteristic carbohydrate-binding proteins LecA and LecB, which play a role in biofilm-formation and lung-infection, can be targeted by glycoconjugates. Here we review the wide range of inhibitors for these proteins (136 references), highlighting structural features and which impact binding affinity and/or therapeutic effects, including carbohydrate selection; linker length and rigidity; and scaffold topology, particularly for multivalent candidates. We also discuss emerging therapeutic strategies, which build on targeting of LecA and LecB, such as anti-biofilm activity, anti-adhesion and drug-delivery, with promising prospects for medicinal chemistry.},\n\tlanguage = {en},\n\tnumber = {12},\n\turldate = {2022-09-07},\n\tjournal = {ChemMedChem},\n\tauthor = {Wojtczak, Karolina and Byrne, Joseph P.},\n\tyear = {2022},\n\tnote = {\\_eprint: https://onlinelibrary.wiley.com/doi/pdf/10.1002/cmdc.202200081},\n\tpages = {e202200081},\n}\n\n","author_short":["Wojtczak, K.","Byrne, J. P."],"key":"wojtczak_structural_2022","id":"wojtczak_structural_2022","bibbaseid":"wojtczak-byrne-structuralconsiderationsforbuildingsyntheticglycoconjugatesasinhibitorsforpseudomonasaeruginosalectins-2022","role":"author","urls":{"Paper":"https://onlinelibrary.wiley.com/doi/abs/10.1002/cmdc.202200081"},"metadata":{"authorlinks":{}},"html":""},"bibtype":"article","biburl":"https://bibbase.org/zotero-mypublications/byrneresearch","dataSources":["LRXjyPDKDiBGAcrph"],"keywords":[],"search_terms":["structural","considerations","building","synthetic","glycoconjugates","inhibitors","pseudomonas","aeruginosa","lectins","wojtczak","byrne"],"title":"Structural Considerations for Building Synthetic Glycoconjugates as Inhibitors for Pseudomonas aeruginosa Lectins","year":2022}